Alex Sapir
Chief Executive Officer chez FULCRUM THERAPEUTICS, INC.
Fortune : 409 318 $ au 31/03/2024
Profil
Alexander C.
Sapir is currently the Chief Executive Officer & Director at ReViral Ltd., the President, Chief Executive Officer & Director at Fulcrum Therapeutics, Inc., and an Independent Director at PhaseBio Pharmaceuticals, Inc. Previously, he held positions as the Senior Director-Marketing at Guilford Pharmaceuticals, Inc., the Director at Dova Pharmaceuticals, Inc., and the Executive Vice President-Marketing & Sales at United Therapeutics Corp.
Mr. Sapir completed his undergraduate degree at Franklin & Marshall College and holds an MBA from Harvard Business School.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 04/03/2024 | 43 360 ( 0,07% ) | 409 318 $ | 31/03/2024 | |
| 19/05/2023 | 3 750 ( 0,01% ) | - $ | 31/01/2024 |
Postes actifs de Alex Sapir
| Sociétés | Poste | Début |
|---|---|---|
| PHASEBIO PHARMACEUTICALS, INC. | Director/Board Member | 12/02/2020 |
| FULCRUM THERAPEUTICS, INC. | Chief Executive Officer | 01/07/2023 |
ReViral Ltd.
 ReViral Ltd. BiotechnologyHealth Technology ReViral Ltd. specializes in the areas of virology and antiviral therapies. It offers drugs to treat respiratory synctial virus infection. The company was founded by Neil Matthews and Stuart Cockerill in 2011 and is headquartered in Stevenage, the United Kingdom. | Chief Executive Officer | 10/06/2019 |
Anciens postes connus de Alex Sapir
| Sociétés | Poste | Fin |
|---|---|---|
| DOVA PHARMACEUTICALS, INC. | Chief Executive Officer | 01/12/2018 |
| UNITED THERAPEUTICS CORPORATION | Sales & Marketing | 01/05/2016 |
Guilford Pharmaceuticals, Inc.
 Guilford Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Guilford Pharmaceuticals Inc. is a pharmaceutical company engaged in the research, development and commercialization of proprietary drugs that target the hospital and neurology markets. Presently, Guilford markets two commercial products, GLIADEL(R) Wafer, for the treatment of brain cancer, and AGGRASTAT(R) Injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome (ACS). Guilford's product pipeline includes a novel anesthetic, AQUAVAN(R) Injection, and drugs for treating Parkinson's disease and peripheral nerve injury | Sales & Marketing | 01/01/2005 |
Formation de Alex Sapir
| Franklin & Marshall College | Undergraduate Degree |
| Harvard Business School | Masters Business Admin |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 3 |
|---|---|
| UNITED THERAPEUTICS CORPORATION | Health Technology |
| PHASEBIO PHARMACEUTICALS, INC. | Health Technology |
| FULCRUM THERAPEUTICS, INC. | Health Technology |
| Entreprise privées | 3 |
|---|---|
Guilford Pharmaceuticals, Inc.
Guilford Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Guilford Pharmaceuticals Inc. is a pharmaceutical company engaged in the research, development and commercialization of proprietary drugs that target the hospital and neurology markets. Presently, Guilford markets two commercial products, GLIADEL(R) Wafer, for the treatment of brain cancer, and AGGRASTAT(R) Injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome (ACS). Guilford's product pipeline includes a novel anesthetic, AQUAVAN(R) Injection, and drugs for treating Parkinson's disease and peripheral nerve injury | Health Technology |
ReViral Ltd.
ReViral Ltd. BiotechnologyHealth Technology ReViral Ltd. specializes in the areas of virology and antiviral therapies. It offers drugs to treat respiratory synctial virus infection. The company was founded by Neil Matthews and Stuart Cockerill in 2011 and is headquartered in Stevenage, the United Kingdom. | Health Technology |
Dova Pharmaceuticals, Inc.
 Dova Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Dova Pharmaceuticals, Inc. operates as a clinical-stage pharmaceutical company, which engages in the acquisition, development and commercialization of drug candidates for rare diseases. It focuses on addressing thrombocytopenia, a disorder characterized by a low blood platelet count. Its drug candidate includes avatrombopag, an orally administered thrombopoietin receptor agonist. The company was founded on March 24, 2016 and is headquartered in Durham, NC. | Health Technology |
